ME03808B - Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji za epitelijalni karcinom jajnika i druge maligne tumore - Google Patents

Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji za epitelijalni karcinom jajnika i druge maligne tumore

Info

Publication number
ME03808B
ME03808B MEP-2020-159A MEP2020159A ME03808B ME 03808 B ME03808 B ME 03808B ME P2020159 A MEP2020159 A ME P2020159A ME 03808 B ME03808 B ME 03808B
Authority
ME
Montenegro
Prior art keywords
cell
cancer
peptide
antibody
nucleic acid
Prior art date
Application number
MEP-2020-159A
Other languages
German (de)
English (en)
French (fr)
Inventor
Heiko Schuster
Janet Peper
Philipp Wagner
Hans-Georg Rammensee
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of ME03808B publication Critical patent/ME03808B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)

Claims (14)

1. Peptid koji sadrži aminokiselinsku sekvencu u skladu sa ID BR. SEKV 82.
2. Peptid u skladu sa patentnim zahtevom 1, naznačen time to navedeni peptid sadrži nepeptidne veze.
3. Peptid u skladu sa patentnim zahtevom 1 ili 2, naznačen time to je navedeni peptid deo fuzionog proteina, naročito koji sadrži N-terminalne aminokiseline HLA-DR antigen-asociranog nepromenljivog lanca (li).
4. T-ćelijski receptor, poželjno rekombinantni, solubilni ili vezan za membranu T-ćelijski receptor koji je reaktivan sa HLA ligandom, naznačeno time što navedeni ligand sadrži aminokiselinsku sekvencu ID BR. SEKV 82.
5. Antitelo, konkretno solubilno ili antitelo vezano za membranu, koje specificno prepoznaje peptid u skladu sa patentnim zahtevom 1, poželjno peptid u skladu sa bilo kojim od patentnog zahteva 1 kada je vezan za MHC molekul.
6. Nukleinska kiselina koja kodira za peptid u skladu sa bilo kojim od patentnih zahteva 1 ili 3 ili za TCR u skladu sa patentnim zahtevom 4, ili antitelo u skladu sa patentnim zahtevom 5, opciono povezana sa heterolognom promoterskom sekvencom, ili vektor ekspresije koji eksprimira navedenu nukleinsku kiselinu.
7. Rekombinantna ćelija domaćin koja sadrži peptid u skladu sa patentnim zahtevom 1 ili 3, ili nukleinsku kiselinu ili vektor ekspresije u skladu sa patentnim zahtevom 6, naznačena time što je navedena ćelija domaćin poželjno antigen-prezentujuća ćelija kao to je dendritična ćelija, ili naznačena time što je navedena ćelija domaćin poželjno T ćelija ili NK ćelija.
8. Metod za proizvodnju peptida u skladu sa bilo kojim od patentnih zahteva 1 ili 3, ili za proizvodnju T-ćelijskog receptora u skladu sa patentnim zahtevom 4, ili antitela u skladu sa patentnim zahtevom 5, pri čemu se metod sastoji od kultivisanja ćelije domaćina u skladu sa patentnim zahtevom 7 koja prezentuje peptid u skladu sa patentnim zahtevom 1, ili eksprimira nukleinsku kiselinu ili vektor ekspresije u skladu sa patentnim zahtevom 6, i izolovanja peptida ili TCR-a ili antitela iz ćelije domaćina ili njenog medijuma za kultivaciju.
9. In vitro metod za proizvodnju aktiviranih T limfocita, pri čemu se metod sastoji od dovodenja u kontakt in vitro T ćelija sa humanim MHC molekulima klase i sa ubačenim antigenom eksprimiranim na površini prikladne antigen-prezentujuće ćelije ili veštačkog konstrukta koji imitira antigen-prezentujuću ćeliju u toku vremenskog perioda koji je dovoljan da se navedene T ćelije aktiviraju na antigen-specifičan način, naznačeno time što je navedeni antigen peptid u skladu sa patentnim zahtevom 1.
10. Aktivirani T limfocit, proizveden pomoću metoda u skladu sa patentnim zahtevom 9, koji selektivno prepoznaje ćeliju koja prezentuje polipeptid koji sadrzi aminokiselinsku sekvencu navedenu u patentnom zahtevu 1.
11. Farmaceutska smeša koja sadrži najmanje jedan aktivan sastojak izabran iz grupe koju čine peptid u skladu sa patentnim zahtevom 1 ili 3, nukleinska kiselina ili vektor ekspresije u skladu sa patentnim zahtevom 6, ćelija u skladu sa patentnim zahtevom 7, aktivirani T limfocit u skladu sa patentnim zahtevom 10 ili antitelo u skladu sa patentnim zahtevom 5 ili T-ćelijski receptor u skladu sa patentnim zahtevom 4, i farmaceutski prihvatljiv nosač, i opciono, dodatne farmaceutski prihvatljive pomoćne materije i/ili stabilizatore.
12. Peptid u skladu sa patentnim zahtevom 1 ili 3, nukleinska kiselina ili vektor ekspresije u skladu sa patentnim zahtevom 6, ćelija u skladu sa patentnim zahtevom 7, aktivirani T limfocit u skladu sa patentnim zahtevom 10 ili antitelo u skladu sa patentnim zahtevom 5 ili T-ćelijski receptor u skladu sa patentnim zahtevom 4 za upotrebu u medicini, poželjno za upotrebu u dijagnostikovanju i/ili lečenju raka.
13. Peptid u skladu sa patentnim zahtevom 1 ili 3, nukleinska kiselina ili vektor ekspresije u skladu sa patentnim zahtevom 6, ćelija u skladu sa patentnim zahtevom 7, aktivirani T limfocit u skladu sa patentnim zahtevom 10 ili antitelo u skladu sa patentnim zahtevom 5 ili T-ćelijski receptor u skladu sa patentnim zahtevom 4 za upotrebu u dijagnostikovanju i/ili lečenju raka u skladu sa patentnim zahtevom 12, naznačenog time sto je navedeni rak izabran iz grupe koju čine rak jajnika, nesitnoćelijski karcinom pluća, sitnoćelijski karcinom pluća, rak bubrega, rak mozga, rak kolona ili rektuma, rak želuca, rak jetre, rak pankreasa, rak prostate, leukemija, rak dojke, karcinom Merkelovih ćelija, melanom, rak jednjaka, rak mokraćne bešike, rak materice, rak žučne kese, rak žučnih puteva i drugi tumori koji pokazuju prekomernu ekspresiju proteina iz kojeg je dobijen peptid u skladu sa ID BR. SEKV 82, konkretno rak jajnika.
14. Komplet koji se sastoji od:a) posude koja sadrti farmaceutsku smešu koja sadrži peptid u skladu sa patentnim zahtevom 1 ili 3, nukleinsku kiselinu ili vektor ekspresije u skladu sa patentnim zahtevom 6, ćeliju u skladu sa patentnim zahtevom 7, aktivirani T limfocit u skladu sa patentnim zahtevom 10 ili antitelo u skladu sa patentnim zahtevom 5 ili T-celijski receptor u skladu sa patentnim zahtevom 4, u rastvoru ili u liofiliziranom obliku;b) opciono, druge posude koja sadrži razblaživač ili rastvor za rekonstituciju za liofiliziranu formulaciju;c) opciono, najmanje još jednog peptida odabranog iz grupe koja se sastoji od ID BR. SEKV 1 do 81 i 83 do 549, id) opciono, uputstva za (i) upotrebu rastvora ili (ii) rekonstituciju i/ili upotrebu liofilizirane formulacije, ie) opciono dalje sadrži jedan ili više od navedenih (iii) pufer, (iv) razblaživač (v) filter, (vi) igla ili (v) brizgalica.
MEP-2020-159A 2015-07-15 2016-07-14 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji za epitelijalni karcinom jajnika i druge maligne tumore ME03808B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562192670P 2015-07-15 2015-07-15
GBGB1512369.8A GB201512369D0 (en) 2015-07-15 2015-07-15 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
EP16739102.8A EP3322717B1 (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
PCT/EP2016/066706 WO2017009400A1 (en) 2015-07-15 2016-07-14 Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Publications (1)

Publication Number Publication Date
ME03808B true ME03808B (me) 2021-04-20

Family

ID=54013984

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2020-159A ME03808B (me) 2015-07-15 2016-07-14 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji za epitelijalni karcinom jajnika i druge maligne tumore

Country Status (36)

Country Link
US (22) US9889159B2 (me)
EP (2) EP3705491A1 (me)
JP (10) JP6862411B2 (me)
KR (2) KR20220075451A (me)
CN (2) CN107922469A (me)
AU (4) AU2016293047B9 (me)
BR (2) BR122023024959A2 (me)
CA (2) CA2992506A1 (me)
CL (5) CL2018000124A1 (me)
CO (1) CO2018000252A2 (me)
CR (4) CR20200408A (me)
CY (1) CY1123505T1 (me)
DK (1) DK3322717T3 (me)
EA (1) EA201890027A1 (me)
ES (1) ES2807832T3 (me)
GB (1) GB201512369D0 (me)
HR (1) HRP20201281T1 (me)
HU (1) HUE049937T2 (me)
IL (3) IL308200A (me)
LT (1) LT3322717T (me)
MA (3) MA42441B1 (me)
MD (1) MD3322717T2 (me)
ME (1) ME03808B (me)
MX (2) MX2018000543A (me)
MY (1) MY189596A (me)
NZ (1) NZ739128A (me)
PE (2) PE20180693A1 (me)
PH (1) PH12018500005A1 (me)
PL (1) PL3322717T3 (me)
PT (1) PT3322717T (me)
RS (1) RS60647B1 (me)
SG (7) SG10202100296PA (me)
SI (1) SI3322717T1 (me)
UA (1) UA124875C2 (me)
WO (1) WO2017009400A1 (me)
ZA (1) ZA201800129B (me)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
TWI796314B (zh) * 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
PE20191248A1 (es) * 2017-01-27 2019-09-18 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PT3428194T (pt) 2017-07-14 2021-11-18 Immatics Biotechnologies Gmbh Molécula de polipéptido com especificidade dupla melhorada
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
JP7470640B2 (ja) 2018-02-09 2024-04-18 イマティクス ユーエス，アイエヌシー． Ｔ細胞を製造する方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
WO2020028562A1 (en) * 2018-07-31 2020-02-06 Loma Linda University Snail sirna-loaded mesoporous silica nanoparticles
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020191172A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) * 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
MA56036A (fr) 2019-05-27 2022-04-06 Immatics Us Inc Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
US20200384028A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
MX2022000046A (es) * 2019-06-25 2022-02-24 Univ Montreal Novedosos antigenos especificos de tumores para cancer de ovario y usos de estos.
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
JP2022543687A (ja) * 2019-08-09 2022-10-13 イマティクス ユーエス，アイエヌシー． ペプチド質量分析断片化を予測するための方法
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US11977057B2 (en) * 2020-06-13 2024-05-07 Complete Omics International Inc. Method and system for neoantigen analysis
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
PE20250846A1 (es) 2020-12-31 2025-03-21 Immatics Us Inc Polipeptidos cd8, composiciones y metodos de uso de estos
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4326858A4 (en) * 2021-04-23 2025-03-12 VLP Therapeutics, Inc. GALECTIN-TARGETED IMMUNOTHERAPY
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
CN113241177B (zh) * 2021-05-19 2024-05-10 上海宝藤生物医药科技股份有限公司 一种评估免疫力水平的方法、装置、设备及存储介质
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024534825A (ja) * 2021-08-24 2024-09-26 イマティクス ユーエス，アイエヌシー． 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択
WO2023044488A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
EP4408468A4 (en) 2021-09-28 2025-07-02 Frontaim Biomedicines Inc MULTIPLE FORMATS OF MOLECULAR COMPLEXES
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用
GB202302709D0 (en) * 2023-02-24 2023-04-12 Genome Res Ltd Method of identifying t cell recpetors of interest
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026096743A1 (en) 2024-10-30 2026-05-07 Immatics US, Inc. Methods for gamma delta t cells manufacturing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003259109A1 (en) * 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
WO2004050860A2 (en) * 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006029176A2 (en) * 2004-09-08 2006-03-16 Ludwig Institute For Cancer Research Cancer-testis antigens
JP4987698B2 (ja) * 2005-03-31 2012-07-25 中外製薬株式会社 癌関連抗原アナログペプチド、およびその利用
EP1806358B1 (en) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
CA2665568C (en) 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
WO2008127285A2 (en) * 2006-10-05 2008-10-23 The Board Of Trustees Of The University Of Arkansas Target peptides for ovarian cancer immunotherapy
DK2183361T3 (en) * 2007-07-27 2015-07-27 Immatics Biotechnologies Gmbh Novel immunotherapy against brain tumors
BRPI0813626A2 (pt) * 2007-07-27 2014-12-23 Immatics Biotechnologies Gmbh Epitopos imunogênicos para a imunoterapia
WO2009032224A2 (en) * 2007-08-29 2009-03-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inhibiting squamous cell carcinoma
RS53872B2 (sr) * 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2014011465A2 (en) * 2012-07-13 2014-01-16 Albert Einstein College Of Medicine Of Yeshiva University Aptamer-targeted antigen delivery
EP2982681B8 (en) * 2013-03-29 2018-11-07 Sumitomo Dainippon Pharma Co., Ltd. Wt1-antigen peptide conjugate vaccine
TWI777194B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
FI3273986T3 (fi) * 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201512369D0 (en) * 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

Also Published As

Publication number Publication date
LT3322717T (lt) 2020-08-25
MA42441B1 (fr) 2020-07-29
US10888587B2 (en) 2021-01-12
CR20200408A (es) 2020-10-08
DK3322717T3 (da) 2020-08-10
CL2019003311A1 (es) 2020-03-13
US10463696B2 (en) 2019-11-05
US20200000849A1 (en) 2020-01-02
SG10202100297QA (en) 2021-02-25
IL292131A (en) 2022-06-01
EA201890027A1 (ru) 2018-06-29
SG10202100292VA (en) 2021-02-25
EP3322717A1 (en) 2018-05-23
JP7074370B2 (ja) 2022-05-24
US10639331B2 (en) 2020-05-05
KR20180030506A (ko) 2018-03-23
US20180117085A1 (en) 2018-05-03
PH12018500005A1 (en) 2018-07-09
BR122023024959A2 (pt) 2024-01-16
HK1253574A1 (en) 2019-06-21
US20210106624A1 (en) 2021-04-15
JP7205919B2 (ja) 2023-01-17
EP3322717B1 (en) 2020-06-10
US20170035807A1 (en) 2017-02-09
US11246889B2 (en) 2022-02-15
UA124875C2 (uk) 2021-12-08
KR20220075451A (ko) 2022-06-08
AU2016293047A1 (en) 2018-02-08
US20210260122A1 (en) 2021-08-26
ZA201800129B (en) 2018-12-19
AU2022200745A1 (en) 2022-02-24
US20190381103A1 (en) 2019-12-19
MA41717A1 (fr) 2019-05-31
MA50542A (fr) 2020-09-09
CA3221097A1 (en) 2017-01-19
CY1123505T1 (el) 2022-03-24
SI3322717T1 (sl) 2020-09-30
ES2807832T3 (es) 2021-02-24
MY189596A (en) 2022-02-18
US20230241106A1 (en) 2023-08-03
US20200000850A1 (en) 2020-01-02
JP7074367B2 (ja) 2022-05-24
US11806366B2 (en) 2023-11-07
US20200316125A1 (en) 2020-10-08
AU2016293047B9 (en) 2020-10-29
SG10202100298SA (en) 2021-02-25
CL2019003310A1 (es) 2020-04-24
GB201512369D0 (en) 2015-08-19
SG10202100291XA (en) 2021-02-25
CL2019003313A1 (es) 2020-03-13
SG10202100296PA (en) 2021-02-25
JP2021000078A (ja) 2021-01-07
CN107922469A (zh) 2018-04-17
US11819518B2 (en) 2023-11-21
CA2992506A1 (en) 2017-01-19
US10869897B2 (en) 2020-12-22
CL2018000124A1 (es) 2018-05-18
PE20180693A1 (es) 2018-04-23
JP7239993B2 (ja) 2023-03-15
CO2018000252A2 (es) 2018-05-31
EP3705491A1 (en) 2020-09-09
SG10202100295RA (en) 2021-02-25
US9889159B2 (en) 2018-02-13
CR20180027A (es) 2018-07-23
AU2020256318A1 (en) 2020-11-12
CN114163501A (zh) 2022-03-11
US11278571B2 (en) 2022-03-22
MX2018000543A (es) 2018-05-22
US10881690B2 (en) 2021-01-05
PE20240645A1 (es) 2024-04-04
US20210252065A1 (en) 2021-08-19
US20230241107A1 (en) 2023-08-03
IL256697A (en) 2018-03-29
HUE049937T2 (hu) 2020-11-30
JP7074369B2 (ja) 2022-05-24
JP2020191862A (ja) 2020-12-03
IL256697B (en) 2022-05-01
US10568909B2 (en) 2020-02-25
JP7239992B2 (ja) 2023-03-15
AU2020203971A1 (en) 2020-07-02
US20210260123A1 (en) 2021-08-26
SG10202100294WA (en) 2021-02-25
NZ739128A (en) 2022-04-29
HRP20201281T1 (hr) 2020-11-13
US11071756B2 (en) 2021-07-27
AU2016293047B2 (en) 2020-09-17
JP6862411B2 (ja) 2021-04-21
US10639332B2 (en) 2020-05-05
JP2020182458A (ja) 2020-11-12
CR20200410A (es) 2020-10-12
AU2022200745B2 (en) 2024-01-18
AU2020203971B2 (en) 2021-11-25
MX2023014146A (es) 2023-12-13
AU2016293047A2 (en) 2018-03-15
US20210252066A1 (en) 2021-08-19
IL308200A (en) 2024-01-01
JP2020198875A (ja) 2020-12-17
US20230201259A1 (en) 2023-06-29
PL3322717T3 (pl) 2020-11-16
BR112017028558A2 (pt) 2018-09-04
JP2020182451A (ja) 2020-11-12
US20210106623A1 (en) 2021-04-15
US20210252064A1 (en) 2021-08-19
US20200316127A1 (en) 2020-10-08
US20230190813A1 (en) 2023-06-22
US20230285458A1 (en) 2023-09-14
MD3322717T2 (ro) 2020-11-30
CR20200409A (es) 2020-10-16
US20200155603A1 (en) 2020-05-21
JP2018531581A (ja) 2018-11-01
US20230086100A1 (en) 2023-03-23
JP2020127401A (ja) 2020-08-27
RS60647B1 (sr) 2020-09-30
CL2019003312A1 (es) 2020-03-13
PT3322717T (pt) 2020-07-27
JP2020167995A (ja) 2020-10-15
JP2020171283A (ja) 2020-10-22
JP2020156480A (ja) 2020-10-01
US10722538B2 (en) 2020-07-28
WO2017009400A1 (en) 2017-01-19
US20200316126A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
HRP20201281T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma
HRP20210709T1 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
HRP20210698T1 (hr) Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
HRP20210076T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma
JP2020191862A5 (me)
JP2020182458A5 (me)
JP2020198875A5 (me)
JP2019516663A5 (me)
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
JP2019513005A5 (me)
JP2021514178A5 (me)
JP2019511214A5 (me)
JP2019515650A5 (me)
HRP20201467T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
JP2021101700A5 (me)
JP2018520653A5 (me)
JP2018536383A5 (me)
HRP20160915T1 (hr) Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
JP2018510628A5 (me)
HRP20230878T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003)
JP2021535900A5 (me)
JP2022502015A5 (me)
HRP20210528T1 (hr) Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma